Global Therapeutic Monoclonal Antibodies Market – Analysis By Source, Target, Indication, Route of administration, By Region, By Country: Market Insights and Forecast (2018-2028)
- USD
Licensing options
Category: Healthcare and Pharmaceutical
Publish Date: December 2022
No. of Pages: 340
Format: Pdf
Licensing options
Executive Summary
According to Azoth Analytics research report, the Therapeutic Monoclonal Antibodies Market is projected to display significant growth represented by a CAGR of 18.63% during 2022–2028. The Global Therapeutic Monoclonal Antibodies Market was valued at USD 334.38 Billion in the year 2021 with the Americas region leading the regional market share.
The Therapeutic Monoclonal Antibodies market's demand has surged in the past year due to the increasing incidence of chronic diseases like cancer, autoimmune disorders, infectious diseases, Neurological and cardiovascular diseases.
America is the largest market for Therapeutic Monoclonal Antibodies with the U.S. accounting for a major share of the total Therapeutic Monoclonal Antibodies consumption in the region.
The European region is a lucrative market and is growing at an exponential rate during the forecast period owing to the rising prevalence of chronic diseases due to the large geriatric population as well as the developed healthcare infrastructure of countries like the United Kingdom and Germany.
Asia Pacific region is the fastest growing region owing to the rapid development and entry of major players in the APAC region and is anticipated to register the fastest growth during the forecast period.
Scope of the Report
• The report presents the analysis of the Therapeutic Monoclonal Antibodies Market for the forecast period of 2023-2028.
• The report analyses the Therapeutic Monoclonal Antibodies Market by Value (USD Billion).
• The report analyses the Therapeutic Monoclonal Antibodies By Source (Humanized, Murine, Chimeric, Human)
• The report analyses the Therapeutic Monoclonal Antibodies Market, By Target (Cell surface antigen, plasma protein or drug, Other Targets, infectious organism)
• The report analyses the Therapeutic Monoclonal Antibodies Market by Indication (Cancer, Infectious Disease, Autoimmune Disorders, Neurological Disorders, Other Indications).
• The report analyses the Therapeutic Monoclonal Antibodies Market by Route of Administration (Intravenous, Subcutaneous, Other ROA).
• The Global Therapeutic Monoclonal Antibodies Market has been analysed By Region (Americas, Europe, Asia Pacific, MEA).
• The Global Therapeutic Monoclonal Antibodies Market has been analysed By Country (United States, Canada, Germany, U.K, France, Spain, Italy, China, Japan, India).
• The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Source, by Target, by Indication, by route of administration
• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Eli Lily and Co., GSK plc, Roche, Astra Zenca plc, Bayer, Amgen, Johnson & Johnson, Pfizer, Novartis, Merck & Co.
Key Target Audience
• Pharmaceutical Companies
• Biotechnology Companies
• Government Bodies & Regulating Authorities
• Investment Banks and Equity Firms
1. Introduction
1.1 Therapeutic Monoclonal Antibodies Market Overview
1.2 Scope of Research
2. Executive Summary
2.1 Market Snapshot
2.2 Regional Insights
2.3 Market Ecosystem Factors
3. Research Methodology
3.1 Data Collection Process
3.2 Market Trajectory Estimation
3.3 Market Size Calculation-Top-to-Bottom
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Trends
4.5 Analyst Recommendations
4.6 Impact Analysis
5. Value Chain Analysis
6. COVID-19 Impact Assessment
6.1 Degree of Impact of COVID-19 on Therapeutic Monoclonal Antibodies Market
6.2 Region-Wise Quarterly Coved Impact Analysis (2020)
7. Porter's five forces analysis
8. Macro Economic Indicator Outlook
8.1 GDP per capita growth (annual %)
8.2 Global Medical Spending
8.3 Current Healthcare Expenditure
8.4 Pharmaceutical Spending/capita
9. Competitive Positioning
9.1 Companies’ Product Positioning
9.2 Market Position Matrix
9.3 Market Share Analysis of Therapeutic Monoclonal Antibodies Market
9.4 Company profiles
9.4.1 Eli-Lily & Co
9.4.2 GSK plc.
9.4.3 Bayer AG
9.4.4 Johnson & Johnson
9.4.5 Amgen
9.4.6 Astra Zeneca plc.
9.4.7 Novartis
9.4.8 Merck & Co., Inc.
9.4.9 Pfizer Inc.
9.4.10 Roche Holding AG
10. Global therapeutic monoclonal antibodies market
10.1 Impact Analysis of Macro Economic Factors on Therapeutic Monoclonal Antibodies Market
10.2 Market Size and CAGR
10.3 Global Therapeutic Monoclonal Antibodies Market: Market Value Assessment
10.4 Market Summary
11 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Source
11.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Source: Snapshot
11.2 Humanized
11.3 Murine
11.4 Chimeric
11.5 Human
12. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Target
12.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Target: Snapshot
12.2 Cell surface antigen
12.3 Plasma protein or drug
12.4 Infectious organism
12.5 Other Targets
13. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Indication
13.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Indication: Snapshot
13.2 Cancer
13.3 Infectious Disease
13.4 Autoimmune Disorders
13.5 Neurological Disorders
13.6 Other Indications
14. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Route of Administration
14.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Indication: Snapshot
14.2 Intravenous
14.3 Subcutaneous
14.4 Other ROA
15. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Region
15.1 Regional Coverage of the Study
16. Americas Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
16.1 Macro Economic Factor Impact Index
16.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
16.3 Americas Therapeutic Monoclonal Antibodies Market: Snapshot
16.4 Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
16.5 Americas Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
16.5.1 By Source
16.5.2 By Target
16.5.3 By Indication
16.5.4 By Route of Administration
16.5.5 By Country
16.5.5.1 United States
16.5.5.2 Canada
16.5.5.3 Brazil
17. Europe Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
17.1 Macro Economic Factor Impact Index
17.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
17.3 Europe Therapeutic Monoclonal Antibodies Market: Snapshot
17.4 Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
17.5 Europe Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
17.5.1 By Source
17.5.2 By Target
17.5.3 By Indication
17.5.4 By Route of Administration
17.5.5 By Country
17.5.5.1 Germany
17.5.5.2 United Kingdom
17.5.5.3 France
17.5.5.4 Italy
17.5.5.5 Spain
17.5.5.6 Rest of Europe
18. Asia Pacific Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
18.1 Macro Economic Factor Impact Index
18.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
18.3 Asia Pacific Therapeutic Monoclonal Antibodies Market: Snapshot
18.4 Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
18.5 Asia Pacific Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
18.5.1 By Source
18.5.2 By Target
18.5.3 By Indication
18.5.4 By Route of Administration
18.5.5 By Country
18.5.5.1 China
18.5.5.2 Japan
18.5.5.3 India
18.5.5.4 Rest of Asia Pacific
19. Middle East & Africa Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
19.1 Macro Economic Factor Impact Index
19.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
19.3 Middle East & Africa Therapeutic Monoclonal Antibodies Market: Snapshot
19.4 Middle East Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
19.5 Middle East & Africa Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
19.5.1 By Source
19.5.2 By Target
19.5.3 By Indication
19.5.4 By Route of Administration
List of Figures
Figure 1: Therapeutic Monoclonal Antibodies Market for next 7 years (in USD Millions)
Figure 2: Therapeutic Monoclonal Antibodies Market Size, By Route of Administration, 2018 & 2028 (USD Million)
Figure 3: Therapeutic Monoclonal Antibodies Market Size by Target, 2021 (%)
Figure 4: Market Share of Prominent Companies of Therapeutic Monoclonal Antibodies, 2021 (%)
Figure 5: Eli Lilly and Company Revenues, 2019-2021 (USD Million)
Figure 6: Eli Lilly and Company Revenues Revenue, By Business Segments, 2021 (%)
Figure 7: Eli Lilly and Company Revenues Revenue, By Business Segments, 2021 (%)
Figure 8: GSK plc. Revenues, 2019-2021 (USD Million)
Figure 9: GSK plc. Revenue, By Business Segments, 2021 (%)
Figure 10: GSK plc. Revenue, By Business Segments, 2021 (%)
Figure 11: Bayer AG. Revenues, 2019-2021 (USD Million)
Figure 12: Bayer AG. Revenue, By Business Segments, 2021 (%)
Figure 13: Bayer AG. Revenue, By Business Segments, 2021 (%)
Figure 14: Johnson & Johnson Revenues, 2019-2021 (USD Million)
Figure 15: J&J Revenue, By Business Segments, 2021 (%)
Figure 16: J&J Revenue, By Business Segments, 2021 (%)
Figure 17: Amgen Pharmaceuticals Revenues, 2019-2021 (USD Million)
Figure 18: Amgen Revenue, By Business Segments, 2021 (%)
Figure 19: Amgen Revenue, By Business Segments, 2020 (%)
Figure 20: Astra Zeneca Revenues, 2019-2021 (USD Million)
Figure 21: Astra Zeneca Revenue, Product Sales by Disease Area, 2021 (%)
Figure 22: Astra Zeneca Revenue, By Geographical Segments, 2021 (%)
Figure 23: Novartis Revenues, 2019-2021 (USD million)
Figure 24: Novartis Revenue, By Business Segments, 2021 (%)
Figure 25: Novartis Revenue, By Business Segments, 2021 (%)
Figure 26: Merck & Co., Inc. Revenues, 2019-2021 (USD Million)
Figure 27: Merck & Co., Inc. Revenue, By Geographic segment, 2021 (%)
Figure 28: Merck & Co., Inc. Revenue, By Business Segments, 2021 (%)
Figure 29: Pfizer Inc. Revenues, 2019-2021 (USD Million)
Figure 30: Pfizer Inc. Revenue, By Business Segments- By Products, 2021 (%)
Figure 31: Pfizer Inc. Revenue, By Business Segments, 2021 (%)
Figure 32: Roche Revenues, 2019-2021 (USD Million)
Figure 33: Roche Revenue, By Business Segments- By Products, 2021 (%)
Figure 34: Roche Revenue, By Business Segments, 2021 (%)
Figure 35a: At a CAGR of 18.63% during 2023-2028, the global market value is expected to reach USD 1076.64 billion in 2028
Figure 35b: Value sales of Therapeutic Monoclonal Antibodies is expected to sustain a staggering sale of 1076.64 billion in 2028
Figure 36: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Region (2022,2028)
Figure 37: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Region (2023-2028)
Figure 38: Global Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 39: Global Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 40: Global Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 41: Global Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 42: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 43: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 44: Global Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 45: Global Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 46: Global Humanized Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 47: Global Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 48: Global Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 49: Global Murine Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 50: Global Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 51: Global Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 52: Global Chimeric, Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 53: Global Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 54: Global Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 55: Global Human, Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 56: Global Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 57: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 58: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 59: Global Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2018-2021 (USD Million)
Figure 60: Global Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2022-2028 (USD Million)
Figure 61: Global Therapeutic Monoclonal Antibodies Market, By Cell surface antigen, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 62: Global Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or drug, By Value, 2018-2021 (USD Billion)
Figure 63: Global Therapeutic Monoclonal Antibodies Market Size, Plasma protein or drug, By Value, 2022-2028 (USD Billion)
Figure 64: Global Therapeutic Monoclonal Antibodies Market, By Plasma protein or drug, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 65: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2018-2021 (USD Billion)
Figure 66: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2022-2028 (USD Billion)
Figure 67: Global Therapeutic Monoclonal Antibodies Market, By Infectious organism, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 68: Global Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 69: Global Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 70: Global Therapeutic Monoclonal Antibodies Market, By Other Targets, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 71: Global Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2021, 2023-2028 (%)
Figure 72: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 73: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 74: Global Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Million)
Figure 75: Global Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Million)
Figure 76: Global Therapeutic Monoclonal Antibodies Market, By Cancer, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 77: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 78: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 79: Global Therapeutic Monoclonal Antibodies Market, By Infectious Disease, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 80: Global Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 81: Global Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 82: Global Therapeutic Monoclonal Antibodies Market, By Autoimmune Disorders, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 83: Global Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 84: Global Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 85: Global Therapeutic Monoclonal Antibodies Market, By Neurological Disorders, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 86: Global Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 87: Global Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 88: Global Therapeutic Monoclonal Antibodies Market, By Other Indications, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 89: Global Therapeutic Monoclonal Antibodies Market CAGR, By Route of Administration, By Value, 2018-2021, 2023-2028 (%)
Figure 90: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Route of Administration (2022,2028)
Figure 91: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Route of Administration (2023-2028)
Figure 92: Global Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Million)
Figure 93: Global Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Million)
Figure 94: Global Therapeutic Monoclonal Antibodies Market, By Intravenous, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 95: Global Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 96: Global Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 97: Global Therapeutic Monoclonal Antibodies Market, By Subcutaneous, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 98: Global Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 99: Global Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 100: Global Therapeutic Monoclonal Antibodies Market, By Other ROA, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 101: Market Value of the Americas is expected to grow from USD 88.15 Bn to USD 467.69 Billion in 2028
Figure 102: Americas Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of 379.54 during 2018-2028
Figure 103: Market Value by Source
Figure 104: Market Value by Target
Figure 105: Top 2 Countries of Therapeutic Monoclonal Antibodies Market in Americas
Figure 106: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Country (2022,2028)
Figure 107: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Country (2023-2028)
Figure 108: Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 109: Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 110: Americas Therapeutic Monoclonal Antibodies Market Share, By Source, 2021 (%)
Figure 111: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 112: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 113: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 114: Americas Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 115: Americas Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 116: Americas Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 117: Americas Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 118: Americas Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 119: Americas Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 120: Americas Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 121: Americas Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 122: Americas Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 123: Americas Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 124: Americas Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 125: Americas Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 126: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 127: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 128: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 129: Americas Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2018-2021 (USD Million)
Figure 130: Americas Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2022-2028 (USD Million)
Figure 131: Americas Cell surface antigen Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 132: Americas Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or drug, By Value, 2018-2021 (USD Billion)
Figure 133: Americas Therapeutic Monoclonal Antibodies Market Size, Plasma protein or drug, By Value, 2022-2028 (USD Billion)
Figure 134: Americas Plasma protein or drug Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 135: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2018-2021 (USD Billion)
Figure 136: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2022-2028 (USD Billion)
Figure 137: Americas Infectious organism Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 138: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 139: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 140: Americas Other Targets Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 141: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2022, 2023-2028 (%)
Figure 142: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 143: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 144: Americas Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Billion)
Figure 145: Americas Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Billion)
Figure 146: Americas Cancer Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 147: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 148: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 149: Americas Infectious Disease Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 150: Americas Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 151: Americas Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 152: Americas Autoimmune Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 153: Americas Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 154: Americas Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 155: Americas Neurological Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 156: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 157: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 158: Americas Other Indications Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 159: Americas Therapeutic Monoclonal Antibodies Market CAGR, By ROA, By Value, 2018-2021, 2023-2028 (%)
Figure 160: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By ROA (2022,2028)
Figure 161: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By ROA (2023-2028)
Figure 162: Americas Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Billion)
Figure 163: Americas Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Billion)
Figure 164: Americas Intravenous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 165: Americas Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 166: Americas Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 167: Americas Subcutaneous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 168: Americas Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 169: Americas Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 170: Americas Other ROA Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 171: United States Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 172: United States Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 173: United States Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 174: United States Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 175: United States Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 176: United States Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 177: United States Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 178: Canada Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 179: Canada Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 180: Canada Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 181: Canada Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 182: Canada Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 183: Canada Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 184: Canada Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 185: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 186: Rest of Americas Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 187: Rest of Americas Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 188: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 189: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 190: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 191: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 192: Market Value of the Europe is expected to grow from USD 79.76 Bn to USD 313.41 Billion in 2028
Figure 193: Europe Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of 233.65 Mn Units during 2018-2028
Figure 194: Market Value by Target
Figure 195: Market Value by Source
Figure 196: Top 3 Countries of Therapeutic Monoclonal Antibodies
Figure 197: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Country (2022,2028)
Figure 198: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Country (2023-2028)
Figure 199: Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 200: Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 201: Europe Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 202: Europe Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 203: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 204: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 205: Europe Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 206: Europe Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 207: Europe Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 208: Europe Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 209: Europe Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 210: Europe Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 211: Europe Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 212: Europe Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 213: Europe Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 214: Europe Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 215: Europe Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 216: Europe Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 217: Europe Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 218: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 219: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 220: Europe Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2018-2021 (USD Billion)
Figure 221: Europe Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2022-2028 (USD Billion)
Figure 222: Europe Cell Surface Antigen Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 223: Europe Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2018-2021 (USD Billion)
Figure 224: Europe Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2022-2028 (USD Billion)
Figure 225: Europe Plasma protein or Drug Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 226: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2018-2021 (USD Billion)
Figure 227: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2022-2028 (USD Billion)
Figure 228: Europe Infectious Organism Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 229: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 230: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 231: Europe Other Targets Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 232: Europe Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2022, 2023-2028 (%)
Figure 233: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 234: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 235: Europe Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Billion)
Figure 236: Europe Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Billion)
Figure 237: Europe Cancer Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 238: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 239: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 240: Europe Infectious Disease Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 241: Europe Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 242: Europe Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 243: Europe Autoimmune Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 244: Europe Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 245: Europe Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 246: Europe Neurological Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 247: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 248: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 249: Europe Other Indications Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 250: Europe Therapeutic Monoclonal Antibodies Market CAGR, By ROA, By Value, 2018-2021, 2023-2028 (%)
Figure 251: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By ROA (2022,2028)
Figure 252: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By ROA (2023-2028)
Figure 253: Europe Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Billion)
Figure 254: Europe Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Billion)
Figure 255: Europe Intravenous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 256: Europe Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 257: Europe Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 258: Europe Subcutaneous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 259: Europe Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 260: Europe Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 261: Europe Other ROA Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 262: Germany Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 263: Germany Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 264: Germany Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 265: Germany Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 266: Germany Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 267: Germany Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 268: Germany Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 269: United Kingdom Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 270: United Kingdom Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 271: United Kingdom Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 272: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 273: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 274: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 275: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 276: France Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 277: France Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 278: France Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 279: France Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 280: France Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 281: France Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 282: France Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 283: Italy Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 270: United Kingdom Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 271: United Kingdom Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 272: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 273: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 274: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 275: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 276: France Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 277: France Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 278: France Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 279: France Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 280: France Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 281: France Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 282: France Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 283: Italy Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 284: Italy Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 285: Italy Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 286: Italy Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 287: Italy Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 288: Italy Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 289: Italy Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 290: Spain Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 291: Spain Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 292: Spain Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 293: Spain Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 294: Spain Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 295: Spain Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 296: Spain Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 297: Rest of Europe Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 298: Rest of Europe Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 299: Rest of Europe Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 300: Rest of Europe Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 301: Rest of Europe Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 302: Rest of Europe Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 303: Rest of Europe Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 304: Market Value of the Asia Pacific is expected to grow from USD 78.06 Bn to USD 108 Billion in 2028
Figure 305: Asia Pacific Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of USD 192.45 Bn during 2018-2028
Figure 306: Market Value by Target
Figure 307: Market Value by Source
Figure 308: Top 3 Countries of Therapeutic Monoclonal Antibodies
Figure 309: Basis Point Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Country (2022,2028)
Figure 310: Market Opportunity Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Country (2023-2028)
Figure 311: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Million)
Figure 312: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Million)
Figure 313: Asia Pacific Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 314: Asia Pacific Therapeutic Monoclonal Antibodies Market CAGR, By Source by Value, 2018-2022, 2023-2028 (%)
Figure 315: Basis Point Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 316: Market Opportunity Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 317: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 318: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 319: Asia Pacific Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 320: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 321: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 322: Asia Pacific Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 323: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 324: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 325: Asia Pacific Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 326: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 327: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 328: Asia Pacific Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 329: Asia Pacific Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 330: Basis Point Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 331: Market Opportunity Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 332: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2018-2021 (USD Billion)
Figure 333: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2022-2028 (USD Billion)
Figure 334: Asia Pacific Cell Surface Antigen Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 335: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2018-2021 (USD Billion)
Figure 336: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2022-2028 (USD Billion)
Figure 337: Asia Pacific Plasma protein or Drug Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 338: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2018-2021 (USD Billion)
Figure 339: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2022-2028 (USD Billion)
Figure 340: Asia Pacific Infectious Organism Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 341: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 342: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 343: Asia Pacific Other Targets Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 344: Asia Pacific Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2022, 2023-2028 (%)
Figure 345: Basis Point Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 346: Market Opportunity Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 347: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Billion)
Figure 348: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Billion)
Figure 349: Asia Pacific Cancer Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 350: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 351: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 352: Asia Pacific Infectious Disease Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 353: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 354: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 355: Asia Pacific Autoimmune Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 356: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 357: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 358: Asia Pacific Neurological Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 359: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 360: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 361: Asia Pacific Other Indications Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 362: Asia Pacific Therapeutic Monoclonal Antibodies Market CAGR, By ROA, By Value, 2018-2021, 2023-2028 (%)
Figure 363: Basis Point Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By ROA (2022,2028)
Figure 364: Market Opportunity Analysis of Asia Pacific Therapeutic Monoclonal Antibodies Market, By ROA (2023-2028)
Figure 365: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Billion)
Figure 366: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Billion)
Figure 367: Asia Pacific Intravenous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 368: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 369: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 370: Asia Pacific Subcutaneous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 371: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 372: Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 373: Asia Pacific Other ROA Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 374: China Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 375: China Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 376: China Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 377: China Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 378: China Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 379: China Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 380: China Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 381: Japan Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 382: Japan Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 383: Japan Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 384: Japan Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 385: Japan Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 386: Japan Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 387: Japan Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 388: India Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 389: India Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 390: India Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 391: India Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 392: India Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 393: India Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 394: India Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 395: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 396: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 397: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 398: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 399: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 400: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 401: Rest of Asia Pacific Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 402: Market Value of the Middle East & Africa is expected to grow from USD 31.82 Bn to USD 42.39 Billion in 2028
Figure 403: Middle East & Africa Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of USD 50.78 Bn during 2018-2028
Figure 404: Market Value by Target
Figure 405: Market Value by Source
Figure 406: Market Value by Route of Administration
Figure 407: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 408: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 409: Middle East & Africa Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 410: Middle East & Africa Therapeutic Monoclonal Antibodies Market CAGR, By Source by Value, 2018-2022, 2023-2028 (%)
Figure 411: Basis Point Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 412: Market Opportunity Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 413: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 414: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 415: Middle East & Africa Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 416: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 417: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 418: Middle East & Africa Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 419: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 420: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 421: Middle East & Africa Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 422: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 423: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 424: Middle East & Africa Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 425: Middle East & Africa Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 426: Basis Point Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 427: Market Opportunity Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 428: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2018-2021 (USD Billion)
Figure 429: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2022-2028 (USD Billion)
Figure 430: Middle East & Africa Cell Surface Antigen Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 431: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2018-2021 (USD Billion)
Figure 432: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2022-2028 (USD Billion)
Figure 433: Middle East & Africa Plasma protein or Drug Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 434: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2018-2021 (USD Billion)
Figure 435: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2022-2028 (USD Billion)
Figure 436: Middle East & Africa Infectious Organism Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 437: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 438: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 439: Middle East & Africa Other Targets Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 440: Middle East & Africa Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2022, 2023-2028 (%)
Figure 441: Basis Point Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 442: Market Opportunity Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 443: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Billion)
Figure 444: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Billion)
Figure 445: Middle East & Africa Cancer Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 446: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 447: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 448: Middle East & Africa Infectious Disease Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 449: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 450: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 451: Middle East & Africa Autoimmune Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 452: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 453: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 454: Middle East & Africa Neurological Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 455: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 456: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 457: Middle East & Africa Other Indications Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 458: Middle East & Africa Therapeutic Monoclonal Antibodies Market CAGR, By ROA, By Value, 2018-2021, 2023-2028 (%)
Figure 459: Basis Point Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By ROA (2022,2028)
Figure 460: Market Opportunity Analysis of Middle East & Africa Therapeutic Monoclonal Antibodies Market, By ROA (2023-2028)
Figure 461: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Billion)
Figure 462: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Billion)
Figure 463: Middle East & Africa Intravenous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 464: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 465: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 466: Middle East & Africa Subcutaneous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 467: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 468: Middle East & Africa Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 469: Middle East & Africa Other ROA Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
List of Tables
Table 1: Global Impact of Drivers and Restraints
Table 2: Key Company Financials, 2019-2021
Table 3: Key Company Financials, 2019-2021
Table 4: Key Company Financials, 2019-2021
Table 5: Key Company Financials, 2019-2021
Table 6: Key Company Financials, 2019-2021
Table 7: Key Company Financials, 2019-2021
Table 8: Key Company Financials, 2019-2021
Table 9: Key Company Financials, 2019-2021
Table 10: Key Company Financials, 2019-2021
Table 11: Key Company Financials, 2019-2021
Table 12: Global Impact of Macro Economic Factors, By Region
Table 13: Americas Impact of Macro Economic Factors, By Country
Table 14: Americas Impact of Drivers and Restraints
Table 15: United States Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 16: United States Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 17: United States Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 18: United States Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 19: United States Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 20: United States Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 21: United States Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 22: United States Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 23: Canada Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 24: Canada Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 25: Canada Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 26: Canada Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 27: Canada Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 28: Canada Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 29: Canada Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 30: Canada Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 31: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 32: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 33: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 34: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 35: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 36: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 37: Rest of Americas Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 38: Rest of Americas Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 39: Europe Impact of Macro Economic Factors, By Country
Table 40: Europe Impact of Drivers and Restraints
Table 41: Germany Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 42: Germany Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 43: Germany Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 44: Germany Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 45: Germany Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 46: Germany Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 47: Germany Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 48: Germany Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 49: United Kingdom Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 50: United Kingdom Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 51: United Kingdom Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 52: United Kingdom Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 53: United Kingdom Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 54: United Kingdom Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 55: United Kingdom Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 56: United Kingdom Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 57: France Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 58: France Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 59: France Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 60: France Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 61: France Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 62: France Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 63: France Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 64: France Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 65: Italy Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 66: Italy Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 67: Italy Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 68: Italy Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 69: Italy Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 70: Italy Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 71: Italy Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 72: Italy Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 73: Spain Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 74: Spain Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2022-2028 (USD Billion)
Table 75: Spain Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2018-2021 (USD Billion)
Table 76: Spain Therapeutic Monoclonal Antibodies Market, By Target, By Value, 2022-2028 (USD Billion)
Table 77: Spain Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2018-2021 (USD Billion)
Table 78: Spain Therapeutic Monoclonal Antibodies Market, By Indication, By Value, 2022-2028 (USD Billion)
Table 79: Spain Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2018-2021 (USD Billion)
Table 80: Spain Therapeutic Monoclonal Antibodies Market, By ROA, By Value, 2022-2028 (USD Billion)
Table 81: Rest of Europe Therapeutic Monoclonal Antibodies Market, By Source, By Value, 2018-2021 (USD Billion)
Table 82: Rest of Eur
Global Pediatric and Maternity Care Market (2023 Edition): Analysis By Services ...
Read More
Global Metabolic Syndrome Market (2023 Edition): Analysis By Indication (NASH, ...
Read More
Global Urinary Incontinence Market (2023 Edition) - Analysis By Incontinence Typ ...
Read More
Global Plasticware Laboratory Consumables Market (2023 Edition): Analysis By Ty ...
Read More
European Optical Retail Market (2023 Edition): Analysis By Product Type (Spectac ...
Read More
Global Affinity Ligands Market (2023 Edition) - Analysis By Type (Antibodies, Ig ...
Read More
Global Acute Migraine Drugs Market - Analysis By Drug Type (Ergot Alkaloids, Ana ...
Read More
Global Liquid Biopsy Market – Analysis by Biomarker Type (CTCs, ctDNA, EVs, Ot ...
Read MoreNo matter the hour, we’re here to help.
Contact us now!.jpg){kind=logo}
Azoth Analytics (ISO 9001:2015) is a business research and analytics company that creates in-depth research reports and provides customized research solutions and consulting services.
@ Copyright 2015 Azoth Analytics | All rights reserved